Loading...
News & Insights2020-02-18T15:42:30+00:00

Pfizer and Takeda deals put spotlight back on value-based pricing programs

Thought Leadership|

Over the last decade, value-based reimbursement models have garnered a mountain of interest, but challenges in building a data infrastructure that can identify outcome metrics and logistics to dispense payments have largely relegated these models to anecdotal status. Recent deals by Pfizer and Takeda may indicate a step forward. Precision’s Ryan Cox weighs in on the evolving state of value based reimbursement models.

(more…)

Treating Mental Health: Pay Now or Pay More Later

Thought Leadership|

Mental health conditions, including depression and anxiety, have skyrocketed over the past two years during the pandemic. This mental health epidemic has sparked innovation among forward-looking leaders in the pharmaceutical and healthcare industries. Precision’s Cynthia Miller and Maureen Hennessey look at some of the newer innovations on the horizon as well as some of the policy changes in play that will accelerate transformation.

(more…)

Upcoming Webinar: Cost-Effectiveness Analysis with R? A Discussion

Events|

Are you involved in preparing health technology assessment (HTA) submissions and in early health economic modeling as part of drug development decision-making? You won’t want to miss our new webinar, “Cost-Effectiveness Analysis with R? A Discussion.” Learn about the pros and cons of R versus Excel in preparing HTA submissions, and the acceptability of R by HTA agencies Wednesday, December 15 at 12:00PM EST.

(more…)

On-Demand Interview: The Science Advisory Board – Precision ADVANCE Aims to Improve Patient Access to Cell and Gene Therapy

Thought Leadership|

Anshul Mangal (President of Project Farma and Precision ADVANCE) and Phil Cyr (SVP, Customer Solutions at Precision Value & Health) sat down with Samantha Black (Editor in Chief at ScienceBoard) to discuss how Precision ADVANCE is driving innovation in the advanced therapy sector by improving patient access through interconnected services across the drug development spectrum. 
(more…)

Load More Posts